EUVIMEDEUVIMED entdecken
Crossref

Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation

Lixia Feng, Wenzhu Hu, Xinying Zeng, Zheng Wei, Yu Long, Mengting Li, Si Sun, Zhide Guo, Xiaoli Lan iD, Xianzhong Zhang iD, Rongqiang Zhuang, Dawei Jiang iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Lixia Feng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Hauptthemen laut MEDLINE: Maleimides, Radiopharmaceuticals, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate a novel albumin-binding strategy for addressing the challenge of insufficient tumor retention of fibroblast activation protein inhibitors (FAPIs). Maleimide, a molecule capable of covalent binding to free thiol groups, was modified to conjugate with FAPI-04 in order to enhance its binding to endogenous albumin, resulting in an extended blood circulation half-life and increased tumor uptake. DOTA-FAPI-maleimide was prepared and radiolabeled with Ga-68 and Lu-177, followed by cellular assays, pharmacokinetic analysis, PET/CT, and SPECT/CT imaging to assess the probe distribution in various tumor-bearing models. Radiolabeling of the modified probe was successfully achieved with a radiochemical yield of over 99% and remained stable for 144 h. Cellular assays showed that the ligand concentration required for 50% inhibition of the probe was 1.20 ± 0.31 nM, and the Kd was 0.70 ± 0.07 nM with a Bmax of 7.94 ± 0.16 fmol/cell, indicative of higher specificity and affinity of DOTA-FAPI-maleimide compared to other FAPI-04 variants. In addition, DOTA-FAPI-maleimide exhibited a persistent blood clearance half-life of 7.11 ± 0.34 h. PET/CT images showed a tumor uptake of 2.20 ± 0.44%ID/g at 0.5 h p.i., with a tumor/muscle ratio of 5.64 in HT-1080-FAP tumor-bearing models. SPECT/CT images demonstrated long-lasting tumor retention. At 24 h p.i., the tumor uptake of [177Lu]Lu-DOTA-FAPI-maleimide reached 5.04 ± 1.67%ID/g, with stable tumor retention of 3.40 ± 1.95%ID/g after 4 days p.i. In conclusion, we developed and evaluated the thiol group-attaching strategy, which significantly extended the circulation and tumor retention of the adapted FAPI tracer. We envision its potential application for clinical cancer theranostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MaleimidesRadiopharmaceuticalsPositron Emission Tomography Computed TomographyAnimalsMiceHumansTissue DistributionCell Line, TumorGallium RadioisotopesRadioisotopesHeterocyclic Compounds, 1-RingFemaleNeoplasmsMice, NudeSingle Photon Emission Computed Tomography Computed TomographyXenograft Model Antitumor AssaysEndopeptidasesMembrane ProteinsTheranostic NanomedicineLutetiumFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

albumin-binderfibroblast activation protein inhibitormaleimidenuclear medicineprolonged circulation

Substanzen

MaleimidesRadiopharmaceuticalsGallium RadioisotopesRadioisotopesHeterocyclic Compounds, 1-RingEndopeptidasesMembrane ProteinsLutetiumFibroblast Activation Protein Alphamaleimide

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • Hubei Key Laboratory of Molecular Imaging, Wuhan 430022, China.
  • State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'An South Road, Xiamen 361102,…
  • Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
  • Department of Nuclear Medicine, The Second Xiangya Hospital, Central South University, No. 139, Renmin Road Central, Changsha, Hunan 410011, China.

ORCID-Profile: Xiaoli Lan, Xianzhong Zhang, Dawei Jiang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Feng, L., Hu, W., Zeng, X., Wei, Z., Long, Y., Li, M., Sun, S., Guo, Z., Lan, X., Zhang, X., Zhuang, R., & Jiang, D. (2024). Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00327

Vancouver

Feng L, Hu W, Zeng X, Wei Z, Long Y, Li M, et al. Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00327

BibTeX
@article{Feng2024,
  author = {Feng, Lixia and Hu, Wenzhu and Zeng, Xinying and Wei, Zheng and Long, Yu and Li, Mengting and Sun, Si and Guo, Zhide and Lan, Xiaoli and Zhang, Xianzhong and Zhuang, Rongqiang and Jiang, Dawei},
  title = {Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00327}
}
Kostenlos starten →